A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies

BACKGROUND: Patients with multiple sclerosis (MS) are commonly treated with anti-CD20 therapies. Reduced seroconversion following COVID-19 vaccination in patients receiving certain anti-CD20 therapies has been reported; however, the immune response following natural infection is poorly characterised...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoll, Sharon, Desai, Shree, Levit, Elle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928678/
https://www.ncbi.nlm.nih.gov/pubmed/36827874
http://dx.doi.org/10.1016/j.msard.2023.104574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928678/
https://www.ncbi.nlm.nih.gov/pubmed/36827874
http://dx.doi.org/10.1016/j.msard.2023.104574

Ejemplares similares